Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12414078 | 0.93 | GPR119 (0.57) | GPR119CYP2C9KCNH2ALDH1A1LMNA | |
| SCHEMBL12505846 | 0.91 | GPR119 (0.61) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12505331 | 0.89 | GPR119 (0.78) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12414251 | 0.89 | GPR119 (0.61) | GPR119CYP2C9KCNH2ALDH1A1LMNA | |
| SCHEMBL12414082 | 0.88 | GPR119 (0.51) | GPR119CYP2C9KCNH2ALDH1A1LMNA | |
| SCHEMBL18538619 | 0.87 | GPR119 (0.80) | GPR119CYP2C9KCNH2ALDH1A1LMNA | |
| SCHEMBL12414085 | 0.81 | GPR119 (0.54) | GPR119CYP2C9KCNH2ALDH1A1LMNA | |
| SCHEMBL12506499 | 0.79 | GPR119 (0.51) | GPR119CYP2C9KCNH2 | |
| SCHEMBL391455 | 0.79 | GPR119 (0.81) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12414067 | 0.79 | GPR119 (0.49) | GPR119CYP2C9KCNH2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | GPR119 1/4885CYP2C9 546/4885KCNH2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.